Larimar Therapeutics Inc (LRMR)

Dec 20, 2024

What is HC Wainwright’s Forecast for LRMR FY2025 Earnings? - Defense World

Dec 20, 2024

Dec 20, 2024

William Blair Has Negative Estimate for LRMR Q1 Earnings - Defense World

Dec 20, 2024

Dec 19, 2024

FY2025 Earnings Estimate for LRMR Issued By HC Wainwright - MarketBeat

Dec 19, 2024

Dec 19, 2024

William Blair Has Pessimistic Outlook of LRMR Q1 Earnings - MarketBeat

Dec 19, 2024

Dec 19, 2024

Charles Schwab Investment Management Inc. Lowers Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Dec 19, 2024

Dec 19, 2024

Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo

Dec 19, 2024

Dec 17, 2024

Larimar Therapeutics announces initial data from OLE study of nomlabofusp - Yahoo Finance

Dec 17, 2024

Dec 17, 2024

Larimar Therapeutics (NASDAQ:LRMR) Given “Buy” Rating at HC Wainwright - Defense World

Dec 17, 2024

Dec 17, 2024

Why Is Larimar Therapeutics Stock Trading Lower On Monday? - AOL

Dec 17, 2024

Dec 16, 2024

Larimar Therapeutics' SWOT analysis: nomlabofusp's potential lifts stock outlook - Investing.com

Dec 16, 2024

Dec 16, 2024

Larimar Therapeutics' (LRMR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Dec 16, 2024

Dec 16, 2024

LRMR Stock Hits 52-Week Low at $3.79 Amid Market Fluctuations - Investing.com Australia

Dec 16, 2024

Dec 16, 2024

LRMR Stock Hits 52-Week Low at $3.79 Amid Market Fluctuations By Investing.com - Investing.com South Africa

Dec 16, 2024

Dec 16, 2024

Larimar Therapeutics stock plunges on clinical study concerns By Investing.com - Investing.com Canada

Dec 16, 2024

Dec 16, 2024

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia - The Manila Times

Dec 16, 2024

Dec 16, 2024

Larimar Therapeutics Announces Positive Initial Data from - GlobeNewswire

Dec 16, 2024

Dec 16, 2024

Larimar's Nomlabofusp Shows Breakthrough Results in Friedreich's Ataxia Treatment, FXN Levels Surge 72% - StockTitan

Dec 16, 2024

Dec 13, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Dec 13, 2024

Dec 11, 2024

Point72 Asset Management L.P. Sells 396,481 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Dec 11, 2024

Dec 08, 2024

When (LRMR) Moves Investors should Listen - Stock Traders Daily

Dec 08, 2024

Dec 07, 2024

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN

Dec 07, 2024

Dec 07, 2024

Janus Henderson Group PLC Grows Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Dec 07, 2024

Dec 05, 2024

Larimar Therapeutics's SWOT analysis: nomlabofusp progress lifts stock outlook By Investing.com - Investing.com Nigeria

Dec 05, 2024

Dec 05, 2024

Larimar Therapeutics's SWOT analysis: nomlabofusp progress lifts stock outlook - Investing.com India

Dec 05, 2024

Dec 02, 2024

Verition Fund Management LLC Decreases Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Dec 02, 2024

Dec 01, 2024

Fred Alger Management LLC Has $5.15 Million Stock Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Dec 01, 2024

Nov 20, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN

Nov 20, 2024

Nov 19, 2024

Larimar Therapeutics (NASDAQ:LRMR) Given Outperform Rating at William Blair - MarketBeat

Nov 19, 2024

Nov 18, 2024

Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 18, 2024

Nov 18, 2024

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 - The Manila Times

Nov 18, 2024

Nov 18, 2024

Larimar Therapeutics Presents Additional Data from Phase 1 - GlobeNewswire

Nov 18, 2024

Nov 18, 2024

Larimar Reports Promising Clinical Data for Friedreich's Ataxia Treatment Nomlabofusp | LRMR Stock News - StockTitan

Nov 18, 2024

Nov 18, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from Analysts - MarketBeat

Nov 18, 2024

Nov 18, 2024

Nomlabofusp shows promise in Friedreich's ataxia study - Investing.com

Nov 18, 2024

Nov 16, 2024

(LRMR) Trading Signals - Stock Traders Daily

Nov 16, 2024

Nov 16, 2024

Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeu - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey

Nov 14, 2024

Nov 14, 2024

Janus Henderson's Strategic Acquisition in Larimar Therapeutics - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Verition Fund Management LLC Reduces Stake in Larimar Therapeuti - GuruFocus.com

Nov 14, 2024

Nov 11, 2024

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart

Nov 11, 2024

Nov 11, 2024

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance

Nov 11, 2024

Nov 08, 2024

PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online

Nov 08, 2024

Nov 06, 2024

Goldman Sachs Group Inc's Strategic Acquisition in Larimar Thera - GuruFocus.com

Nov 06, 2024

Nov 04, 2024

Research Analysts Offer Predictions for LRMR FY2024 Earnings - Defense World

Nov 04, 2024

Nov 04, 2024

What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat

Nov 04, 2024

Nov 02, 2024

HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World

Nov 02, 2024

Nov 02, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024

Nov 01, 2024

Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com

Nov 01, 2024

Oct 31, 2024

Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat

Oct 31, 2024